AUB ScholarWorks

Managing unresponsiveness or intolerance to deferasirox therapy: A tale of two doses

Show simple item record

dc.contributor.author Musallam K.M.
dc.contributor.editor
dc.date 2011
dc.date.accessioned 2017-10-05T15:39:39Z
dc.date.available 2017-10-05T15:39:39Z
dc.date.issued 2011
dc.identifier 10.1586/ehm.11.36
dc.identifier.isbn
dc.identifier.issn 17474086
dc.identifier.uri http://hdl.handle.net/10938/17013
dc.description.abstract Evaluation of: Chang HH, Lu MY, Liao YM et al. Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia. Pediatr. Blood Cancer 56(3), 420-424 (2011). Chronic transfusional iron overload leads to significant morbidity and mortality in patients with β-thalassemia major. The once-daily oral iron chelator, deferasirox, opened new horizons for the management of transfusional siderosis. A large body of evidence is now available regarding its efficacy and safety. Nevertheless, some patients remain unresponsive or intolerant to the adverse events of the drug. Chang et al. evaluated the benefit of twice-daily dosing in this setting. The authors concluded that twice-daily deferasirox improves responsiveness and tolerability. Even though the study included only a small number of patients, it offers promising insights that should be interpreted with caution. © 2011 Expert Reviews Ltd.
dc.format.extent
dc.format.extent Pages: (411-414)
dc.language English
dc.publisher LONDON
dc.relation.ispartof Publication Name: Expert Review of Hematology; Publication Year: 2011; Volume: 4; no. 4; Pages: (411-414);
dc.relation.ispartofseries
dc.relation.uri
dc.source Scopus
dc.subject.other
dc.title Managing unresponsiveness or intolerance to deferasirox therapy: A tale of two doses
dc.type Article
dc.contributor.affiliation Musallam, K.M., Department of Internal Medicine, Division of Hematology and Oncology, American University of Beirut Medical Center, Beirut, Lebanon
dc.contributor.authorAddress Musallam, K.M.; Department of Internal Medicine, Division of Hematology and Oncology, American University of Beirut Medical Center, Beirut, Lebanon; email: kmm06@aub.edu.lb
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine; Division: Hematology-Oncology;
dc.contributor.authorDepartment Internal Medicine
dc.contributor.authorDivision Hematology-Oncology
dc.contributor.authorEmail kmm06@aub.edu.lb
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials Musallam, KM
dc.contributor.authorOrcidID
dc.contributor.authorReprintAddress Musallam, KM (reprint author), Amer Univ Beirut Med Ctr, Dept Internal Med, Div Hematol and Oncol, Beirut, Lebanon.
dc.contributor.authorResearcherID
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Angelucci E, 2000, NEW ENGL J MED, V343, P327, DOI 10.1056-NEJM200008033430503; Berdoukas V, 2010, ANN HEMATOL, V89, P1177, DOI 10.1007-s00277-010-0933-1; Cappellini MD, 2007, CLIN THER, V29, P909, DOI 10.1016-j.clinthera.2007.05.007; Cappellini MD, 2010, HAEMATOL-HEMATOL J, V95, P557, DOI 10.3324-haematol.2009.014696; Cappellini MD, 2008, EXPERT OPIN PHARMACO, V9, P2391, DOI [10.1517-14656566.9.13.2391 , 10.1517-14656560802335333]; CAPPELLINI MD, 2009, BLOOD, V114, P4063; Cappellini MD, 2006, BLOOD, V107, P3455, DOI 10.1182-blood-2005-08-3430; Chang HH, 2011, PEDIATR BLOOD CANCER, V56, P420, DOI 10.1002-pbc.22826; Chirnomas D, 2009, BLOOD, V114, P4009, DOI 10.1182-blood-2009-05-222729; Farmaki K, 2011, BLOOD CELL MOL DIS, V47, P33, DOI 10.1016-j.bcmd.2011.03.007; Galanello R, 2010, ANN NY ACAD SCI, V1202, P79, DOI 10.1111-j.1749-6632.2010.05591.x; Pennell DJ, 2011, HAEMATOL-HEMATOL J, V96, P48, DOI 10.3324-haematol.2010.031468; Ponticelli C, 2010, BLOOD REV, V24, P239, DOI 10.1016-j.blre.2010.08.004; Rienhoff HY, 2011, HAEMATOL-HEMATOL J, V96, P521, DOI 10.3324-haematol.2010.034405; Taher A, 2010, ACTA HAEMATOL-BASEL, V123, P220, DOI 10.1159-000313447; Taher A, 2009, BRIT J HAEMATOL, V147, P752, DOI 10.1111-j.1365-2141.2009.07908.x; Telfer PT, 2000, BRIT J HAEMATOL, V110, P971, DOI 10.1046-j.1365-2141.2000.02298.x; Trachtenberg F, 2011, AM J HEMATOL, V86, P433, DOI 10.1002-ajh.21993; Vichinsky E, 2008, AM J HEMATOL, V83, P398, DOI 10.1002-ajh.21119; Wood JC, 2008, BLOOD REV, V22, pS14, DOI 10.1016-S0268-960X(08)70004-3
dc.description.citedCount
dc.description.citedTotWOSCount 0
dc.description.citedWOSCount 0
dc.format.extentCount 4
dc.identifier.articleNo
dc.identifier.coden
dc.identifier.pubmedID
dc.identifier.scopusID 79961069812
dc.identifier.url
dc.publisher.address UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND
dc.relation.ispartofConference
dc.relation.ispartofConferenceCode
dc.relation.ispartofConferenceDate
dc.relation.ispartofConferenceHosting
dc.relation.ispartofConferenceLoc
dc.relation.ispartofConferenceSponsor
dc.relation.ispartofConferenceTitle
dc.relation.ispartofFundingAgency
dc.relation.ispartOfISOAbbr Expert Rev. Hematol.
dc.relation.ispartOfIssue 4
dc.relation.ispartOfPart
dc.relation.ispartofPubTitle Expert Review of Hematology
dc.relation.ispartofPubTitleAbbr Expert Rev. Hematol.
dc.relation.ispartOfSpecialIssue
dc.relation.ispartOfSuppl
dc.relation.ispartOfVolume 4
dc.source.ID WOS:000293866300011
dc.type.publication Journal
dc.subject.otherAuthKeyword deferasirox
dc.subject.otherAuthKeyword dosing
dc.subject.otherAuthKeyword iron chelation
dc.subject.otherAuthKeyword iron overload
dc.subject.otherAuthKeyword thalassemia major
dc.subject.otherChemCAS deferasirox, 201530-41-8
dc.subject.otherIndex deferasirox
dc.subject.otherIndex amylase blood level
dc.subject.otherIndex arthralgia
dc.subject.otherIndex article
dc.subject.otherIndex beta thalassemia
dc.subject.otherIndex dosage schedule comparison
dc.subject.otherIndex dose response
dc.subject.otherIndex drug efficacy
dc.subject.otherIndex drug hypersensitivity
dc.subject.otherIndex drug response
dc.subject.otherIndex drug safety
dc.subject.otherIndex drug tolerability
dc.subject.otherIndex gastrointestinal pain
dc.subject.otherIndex human
dc.subject.otherIndex iron overload
dc.subject.otherIndex major clinical study
dc.subject.otherIndex priority journal
dc.subject.otherIndex side effect
dc.subject.otherKeywordPlus ORAL IRON CHELATOR
dc.subject.otherKeywordPlus THALASSEMIA MAJOR PATIENTS
dc.subject.otherKeywordPlus BETA-THALASSEMIA
dc.subject.otherKeywordPlus SERUM FERRITIN
dc.subject.otherKeywordPlus CARDIAC IRON
dc.subject.otherKeywordPlus OVERLOAD
dc.subject.otherKeywordPlus COMPLICATIONS
dc.subject.otherKeywordPlus ICL670
dc.subject.otherWOS Hematology


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


Browse

My Account